Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

CNS tumours

3263 - Prognostic factors for IDH mutant molecular astrocytomas

Date

09 Sep 2017

Session

CNS tumours

Presenters

Santino Minichillo

Citation

Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366

Authors

S. Minichillo1, E. Franceschi1, A. Mura1, A. Mandrioli1, A. Tosoni1, G. Tallini2, A. Pession3, M.P. Foschini4, C. Bortolotti5, D. Danieli6, A. Talacchi7, L. Cirillo8, S. Bartolini1, A. Paccapelo1, A.A. Brandes1

Author affiliations

  • 1 Medical Oncology, Ausl / Irccs Institute Of Neurological Sciences, Bellaria Hospital, 40139 - Bologna/IT
  • 2 Department Of Medicine (dipartimento Di Medicina Specialistica, Diagnostica E Sperimentale) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna School of Medicine, Bologna/IT
  • 3 Department Of Pharmacy And Biotechnology (dipartimento Di Farmacia E Biotecnologie) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna/IT
  • 4 Department Of Biomedical And Neuromotor Sciences (dibinem), Section Of Pathology, M. Malpighi, Bellaria Hospital, University of Bologna, Bologna/IT
  • 5 Neurosurgery, Ausl / Irccs Institute Of Neurological Sciences, Bellaria Hospital, 40139 - Bologna/IT
  • 6 Departments Of Pathology, ULSS Vicenza, Vicenza/IT
  • 7 Department Of Neurological, Neuropsychological, Morphological And Movement Sciences, Section Of Neurosurgery, University of Verona, University Hospital, Verona/IT
  • 8 Neuroradiology, Ausl / Irccs Institute Of Neurological Sciences, Bellaria Hospital, 40139 - Bologna/IT
More

Resources

Abstract 3263

Background

Low grade glioma (LGG) is a heterogeneous disease. Recently, the 2016 WHO classification of brain tumors has underlined the role of genetic and molecular features. Molecular astrocytomas have been defined as grade II tumors with IDH mutation and without 1p19q codeletion.

Methods

We evaluated 213 consecutive patients with LGG who received surgery or biopsy and had adequate tissue to assess molecular characterization. IDH mutations were assessed by immunohystochemistry (IHC) and next generation sequencing (NGS) in IHC negative cases, MGMT methylation status was assessed by polymerase chain reaction (PCR) and 1p19q deletion was assessed by fluorescence in situ hybridation (FISH).

Results

198 patients (93.0%) showed IDH-mutation. Ninety patients (49.2%) were 1p19q non codeleted (molecular astrocytomas). The median follow up was 98.3 months. Median age was 36 (range: 18-69), 11 patients (12.2%) underwent biopsy, 48 (53.3%) patients subtotal resection and 31 (34.4%) patients total resection. According to RTOG criteria, 68 patients (75.6%) were considered high risk (> 40 years and/or incomplete resection), and 22 patients (24.4%) were considered low risk (< 40 years and/or complete resection). 59 patients (65.5%) did not receive any post-surgical treatment, but only follow-up, 31 patients (34.4%) received post-surgical treatments: 20 (22.2%) received radiotherapy (RT), 7 (7.8%) received chemotherapy (CT), 4 (4.4%) received CT+RT. Median progression-free survival (PFS) was 44.3 months. Significant differences in PFS were observed between treated and untreated patients (64.8 vs 35.7 months p = 0.004) and treated with RT versus follow-up (60.0 vs 35.7 months p = 0.004). Multivariate analysis confirmed the treatment after surgery as an independent prognostic factor (HR 0.456, p = 0.005). Median overall survival (OS) was 164.0 months. At time of analysis no significant differences in OS were available.

Conclusions

Post-surgical treatment after resection of IDH mutant molecular astrocytomas is an independent prognostic factor. A longer follow-up is needed for worthy results in terms of OS.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.